IP Library Granted Patent US 12,129,492
Granted Patent B2
US 12,129,492 · App. 17/343,411 · Granted Oct 29, 2024

Human liver microphysiology platform and self assembly liver acinus model and methods of their use

Inventors: D. Lansing Taylor (Pittsburgh, PA); Albert Gough (Glenshaw, PA); Larry Vernetti (Wexford, PA)
C12N5/0697B01L3/502715B01L3/502761C12M23/16C12M35/08C12N5/067G01N33/5067G01N33/5082B01L2300/0636C12N2502/11C12N2502/14C12N2502/28C12N2510/00C12N2513/00C12N2533/50C12N2533/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,129,492
App. No.
17/343,411
Granted
Oct 29, 2024
Kind
B2
Abstract

Microfluidic devices for modeling three-dimensional tissue structures and methods for making and using the same are described herein.

Claims (38)

1. A method for self-assembly of liver acini comprising:

providing a surface coated with an extracellular matrix protein;

contacting the surface with parenchymal hepatic cells to form self-assembled cord formations on the extracellular matrix proteins;

incubating the surface contacted with the parenchymal hepatic cells for about 12 to about 16 hours;

contacting the surface with endothelial cells, immune cells, or combinations thereof;

incubating the surface contacted with endothelial cells or immune cells, or combinations thereof for about 1 to about 12 hours, thereby forming three-dimensional structures of liver acini; and

contacting the surface with polymerized collagen.

2. The method of claim 1 , wherein the surface is disposed within a microfluidic device.

3. The method of claim 2 , wherein contacting the surface with polymerized collagen comprises:

introducing collagen into the microfluidic device;

inverting the microfluidic device;

polymerizing the collagen; and

inverting the microfluidic device.

4. The method of claim 2 , wherein the microfluidic device comprises:

a housing having at least one inlet and at least one outlet; and

a flow medium contacting one or more of the parenchymal hepatic cells, the endothelial cells, the immune cells, or a combination thereof.

5. The method of claim 4 , wherein the parenchymal hepatic cells together with the endothelial cells, the immune cells, or combinations thereof form the three-dimensional structures within the housing.

6. The method of claim 4 , further comprising a pump fluidly connected to the inlet configured to propel flow medium through the housing.

7. The method of claim 4 , wherein the housing comprises one or more chambers and one or more passages fluidly connecting the chambers.

8. The method of claim 7 , wherein the extracellular matrix proteins are disposed in the chambers of the housing.

9. The method of claim 4 , further comprising a sensor positioned to detect analytes in effluent exiting the housing.

10. The method of claim 4 , further comprising an imager positioned to image the three-dimensional structures.

11. The method of claim 4 , further comprising one or more ports positioned to introduce substances into the flow medium.

12. The method of claim 1 , wherein the parenchymal hepatic cells further comprise genetically modified hepatocytes expressing a genetically encoded fluorescence based biosensor.

13. The method of claim 12 , wherein expression of the genetically encoded fluorescence based biosensor is dependent upon calcium levels, pH, glutathione levels, mitochondrial calcium levels, oxidative stress, or reactive oxygen species.

14. The method of claim 12 , wherein expression of the genetically encoded fluorescence based biosensor is in response to apoptosis, change in mitochondrial membrane potential, cell proliferation, free calcium ion concentration, cell motility, and oxidative stress response.

15. The method of claim 1 , wherein the parenchymal hepatic cells comprise one or more of cultured hepatocytes, hepatocytes derived from induced pluripotent stem cells, and primary hepatocytes, endothelial cells, immune cells, stellate cells, and combinations thereof.

16. The method of claim 1 , wherein the one or more three-dimensional structures have established zonation.

17. The method of claim 1 , wherein the contacting the surface with endothelial cells, immune cells, or combinations thereof comprises contacting the surface with parenchymal hepatic cells, endothelial cells, and immune cells.

18. The method of claim 1 , wherein the incubating the surface for about 1 to about 12 hours comprises incubating the parenchymal hepatic cells, endothelial cells, immune cells, or combinations thereof for about 1 to about 12 hours in a flow medium.

19. The method of claim 1 , wherein the cords comprise rows of two or more parenchymal hepatic cells that vary in length and width.

20. A method for self-assembly of liver acini comprising:

providing a surface coated with an extracellular matrix protein;

contacting the surface with parenchymal hepatic cells;

incubating the surface for about 12 to about 16 hours;

contacting the surface with endothelial cells and immune cells;

incubating the parenchymal hepatic cells, endothelial cells and immune cells for about 1 to about 12 hours, thereby forming three-dimensional structures of liver acini; and

contacting the surface with polymerized collagen.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2024
From: NORTIS, INC.
To: QURIS TECHNOLOGIES LTD.
Reel/Frame 068618/0221 →
LICENSE Recorded Aug 26, 2024
From: UNIVERSITY OF PITTSBURGH
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 068790/0810 →
Continuity (3)
Division 15515837
Provisional Application 62057625 · Sep 30, 2014
Related Publication 20210301261A1 · Sep 30, 2021